Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies

Jian-Xuan Sun, Chen-Qian Liu, Xing-Yu Zhong, Jin-Zhou Xu, Ye An, Meng-Yao Xu, Jia Hu, Zong-Biao Zhang*, Qi-Dong Xia†, and Shao-Gang Wang*

Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background: Numerous studies have reported the role of statins on biochemical recurrence (BCR) among patients with prostate cancer (PCa) after definitive treatment. However, the conclusions of these studies are contradictory. We aimed to determine the effect of statins on BCR of PCa using a systematic review and meta-analysis.

Methods: We searched PubMed (Medline) and other databases for cohort studies evaluating the effect of statins on the BCR of patients with PCa between January 1, 2000, and December 31, 2021. The random effects (RE) model and quality effects (QE) model were used to calculate the pooled hazard ratio (pHR) and pooled risk ratio (pRR) and their 95% confidence interval (95% CI).

Results: A total of 33 cohort studies were finally selected and included in this systematic review and meta-analysis. Statin use was significantly associated with a 14% reduction in the HR of BCR (pHR: 0.86, 95% CI: 0.78 to 0.95, I² = 64%, random effects model, 31 studies) and a 26% reduction in the RR of BCR (pRR: 0.74, 95% CI: 0.57 to 0.94, 24,591 patients, I² = 88%, random effects model, 15 studies) among patients with PCa. The subgroup analyses showed that statins could result in 22% reduction in the HR of BCR (pHR: 0.78, 95% CI: 0.61 to 0.98, I² = 57%, random effects model) among patients accepting radiotherapy (RT).

Conclusions: Our study suggests that statins have a unique role in the reduction of BCR in patients with PCa after definite treatment, especially RT. In the future, more clinical trials and in vitro and animal experiments are needed to further verify the effects of statins in PCa and the potential mechanisms.

Keywords: statins, prostate cancer, biochemical recurrence, meta-analysis, radical prostatectomy, radiotherapy
INTRODUCTION

Prostate cancer (PCa) has the second highest incidence and the fifth highest mortality among all the malignant tumors in men around the world, causing more than 1,600,000 new cases and approximately 366,000 deaths annually (1). According to the data provided by the Global Burden of Disease Database, in 2017, there were 144,887 newly diagnosed PCa and 51,718 deaths in China, and the incidence of PCa is increasing year by year, which brought a heavy burden to public health and the national economy (2). Despite the high incidence, patients with non-metastatic PCa could choose various treatments such as active surveillance, radical prostatectomy (RP) and pelvic lymph node dissection (PLND), radiotherapy (RT), and androgen deprivation therapy (ADT) according to the stage of disease and the prognosis is good for those with low risk PCa (3). After treatment with curative intent, the measurement of prostate-specific antigen (PSA) becomes the most validated and sensitive method to monitor relapse (4). biochemical recurrence (BCR) is defined as the return of detectable PSA, and nearly 20%-40% men treated with RP (5) or 30%-50% of those treated with RT will develop BCR (6), which indicates a nearly 30% probability of clinical recurrence after RP (7) and approximately 16.4% probability of death (8). Since BCR is one of the strongest evidences for clinical recurrence and progression of PCa, it is urgent for us to find effective treatment and protective factors to decrease the risk of BCR and improve the survival of patients after primary treatments.

Statins are 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, which could inhibit the cholesterol synthesis by suppressing the activity of the rate-limiting enzyme in the liver. As commonly used drugs for secondary prevention of cardiovascular disease, statins are widely used worldwide. A cross-sectional study based on a total of 2,613,035 participants in 31 provinces in China showed that about 19.3% of them had ever used or were using statins (9). Although the role of statins in preventing cardiovascular disease by improving hypercholesterolemia is indisputable, in recent years, increasing evidence has suggested that statins also play a non-negligible role in chemoprevention and treatment of other diseases such as erectile dysfunction possibly by improving hyperhomocysteinemia (10, 11), and advanced tumors, including colon cancer, pancreatic cancer, and PCa (12–17). Existing studies have shown that the effects of statins on PCa are mainly achieved through two kinds of mechanisms: cholesterol-mediated and non-cholesterol-mediated pathways (18). Statins could influence the growth and progression of PCa mainly by cholesterol-mediated pathways. A positive correlation between cholesterol accumulation in prostate tissue and PCa incidence was reported as early as 1981 (19). Several mechanisms have demonstrated that dysregulation of cholesterol homeostasis in prostate cells contributes to the development of PCa. One study found that hypermethylation of the ABCA1 promoter resulted in a decreased expression of cholesterol efflux transporters, resulting in lower cholesterol efflux rates and increased cholesterol levels in prostate cancer cells. The presence of this epigenetic alteration is associated with high-grade prostate cancer (20). In addition, the mTOR pathway is also important in the regulation of sterol regulatory element-binding proteins (SREBPs), which are important transcription factors that control lipid and cholesterol homeostasis (21). A study reported that the intracellular accumulation of cholesterol lipid droplets is driven by loss of expression of the tumor-suppressor PTEN and subsequent activation of the PI3K-AKT-mTOR signaling pathway, which is also connected with high-grade prostate cancer in humans (22). The areas of cholesterol accumulation on the cell membrane are called lipid rafts, which could initiate downstream signaling pathways and lead to the growth and development of PCa. Statins could reduce the level of cholesterol and affect the formation of lipid rafts on the cell membrane, thereby affecting the androgen receptor (AR) pathway, epidermal growth factor receptor (EGFR) pathway, luteinizing hormone receptor pathway, and others (23–25), thus inhibiting downstream signaling pathways such as AKT and JAK-STAT3 (26), and then suppressing tumor cell growth and promoting cell apoptosis. Therefore, statins could affect the accumulation of cholesterol and block the necessary survival signals needed by tumors.

Additionally, cholesterol is the precursor of androgen, so statins can affect the synthesis of intracellular androgen by reducing the level of serum cholesterol, thereby affecting the growth of prostate cancer cells. An randomized controlled trial (RCT) showed that 80 mg/day of atorvastatin was associated with a reduction in serum androgen levels in PCa patients, but whether androgen levels in prostate tissue were also significantly reduced remains to be studied (27). Besides, statins could also suppress cancer cell proliferation by reducing the levels of mevalonate (MVA) and isoprenoids derived from it, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which were essential for posttranslational modifications of a variety of proteins called protein prenylation. Protein prenylation was important for the localization, membrane anchoring, and function of numerous signaling proteins, including Rho-GTPase family members such as Ras and the Rho GTPases, which could function as intermediators between extra- and intracellular signaling and regulate the activity of several kinases to regulate different physiological processes (28). Rho GTPases were tightly coconnected with growth-promoting pathways like mTOR and MAPK signaling pathways and contributed to tumorigenesis, metastasis, and drug resistance (29). Besides, the mevalonate pathway could influence Hippo/YAP signaling, which was important in tissue proliferation and tumorigenesis (30). Furthermore, statins could possibly induce apoptosis in cancer cells independent of their effect on cholesterol levels by suppressing cyclin–dependent kinase 2 (CDK2) or activating caspases and promoting cell-cycle arrest in PCa (31, 32).

More than 60 studies have reported the interaction between statin use and the prognosis of patients with PCa after definite treatment, including BCR, prostate cancer-specific mortality (PCSM), and overall survival (OS). The results of most literatures are encouraging but contradictory at the same time, which indicates that the effect of statins on the prognosis of PCa patients remains controversial. A meta-analysis of 34
observational studies published in 2016 showed that statin use could significantly reduce the risk of biochemical recurrence (BCR) in patients receiving RT (HR: 0.79, 95% CI: 0.65, 0.95, p = 0.01), but there was no statistically significant reduction in BCR risk in patients treated with RP (HR: 0.94, 95% CI: 0.81, 1.09, p = 0.43). Meanwhile, statins have a significant effect on the reduction of tumor metastasis, all-cause mortality, and PCSM after treatment (33). The investigators also observed a significant heterogeneity in the included studies. Since many new studies have been published since 2016, we decided to conduct this systematic review and meta-analysis to reevaluate the association between statin use and the risk of BCR among patients with prostate cancer after definite treatments.

MATERIALS AND METHODS

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 reporting guideline (34).

Criteria for Study Selection

All the studies were included into this systematic review and meta-analysis if they met the following criteria: (1) the exposure of interest was statin use; (2) the study design was cohort; (3) the outcome of interest was BCR of prostate cancer; (4) the follow-up ≥ 6 months; and (5) risk estimates and 95% confidence intervals (CIs) were reported (or information to calculate them). The animal studies, in vitro studies, RCTs, and case-control studies were excluded. No language or publication status limits were applied.

Literature Search and Search Procedure

We searched PubMed (Medline), EMBASE, and Cochrane Library for cohort studies evaluating the effects of statins on the BCR of patients with prostate cancer between January 1, 2000, and December 31, 2021. We also searched Google Scholar to retrieve gray literatures such as meeting abstracts. We searched these databases using key words such as “statins,” “HMG-CoA inhibitor,” “prostate cancer,” and “prostatic neoplasms.” The detailed search strategy for each database is reported in Supplementary Table 1 with keywords and the number of retrieved citations per string. During the screening procedure, two reviewers (J-XS and X-YZ) independently searched abstracts and selected them according to the search criteria. The inter-rater kappa statistic was calculated to evaluate the consistency between the two authors for using the inclusion and exclusion criteria. Discrepancies about the inclusion or exclusion were resolved by consensus of the third author (Q-DX). The EndNote application (version X9) was used to remove the duplicates and apply the inclusion criteria. We utilized a PRISMA flowchart to depict the literature search procedure (Figure 1).

Data Extraction

Three authors (J-XS, C-QL, and Q-DX) independently extracted information from the included studies using a designed data extraction sheet. The data extraction sheet consisted of bibliographic information and background information. Bibliographic information included author name, year of publication, and journal name and title. Background information included the inclusion and exclusion criteria for patients, age, follow-up period, body mass index (BMI), the level of serum cholesterol, race, the level of PSA, Gleason score (GS), tumor stage, primary treatment, the definition of statin use, the dose and median duration of usage of statins, definition of BCR, the number of patients, the number of statin users, and the number of patients with BCR. Moreover, we also extracted the data about the outcomes. The primary outcome of interest for this study was BCR. The adjusted multivariate hazard ratio (HR) and risk ratio (RR) with corresponding 95% confidence intervals (CIs) were used to assess the potential association between statin use and BCR after primary treatment.

Literature Quality Assessment

We adapted the Newcastle–Ottawa scale (NOS) tool to assess the risk of bias of the included cohort studies. The NOS consists of three categories (Selection, Comparability, and Outcome) and a total of eight items (Table 2). A study can be awarded a maximum of one point for each numbered item within the Selection and Outcome categories, and a maximum of two points can be given for Comparability (68). Therefore, a study can be awarded at most nine points in total. The quality of the studies was considered as good, fair, or poor based on the Agency of Healthcare Research and Quality (AHRQ) standards using the scores obtained from the NOS (69).

Data Synthesis and Analysis

We calculated a pooled hazard ratio (pHR) and a pooled risk ratio (pRR) with 95% confidence interval (CI) for BCR reported in the included studies using random effects (RE) models and quality effects (QE) models, respectively. We analyzed the heterogeneity between studies using the standard Cochrane chi-square $\chi^2$ (Cochrane’s Q) test with a significance level of $\alpha = 0.10$ and the $I^2$ test. An $I^2$ statistic $\geq 50\%$ indicates a considerable level of heterogeneity. The L’Abbé plot and Galbraith plot were used to visually display the heterogeneity of included studies. We performed subgroup analyses stratified by parameters such as primary treatment and country to find out the potential source of heterogeneity. We also performed meta-regression using parameters such as age, follow-up duration, publication year, PSA level, BMI (value or the percentage of BMI < 30 kg/m$^2$), serum cholesterol level, percentage of patients in tumor stage $\geq T3$, percentage of patients with Gleason score $\geq 7$, and percentage of patients with black race, which could be responsible for the differences in the outcomes observed among the studies. We determined the presence of publication bias in observational studies using both the Begg’s (70) and Egger’s (71) tests. A contour-enhanced funnel plot was utilized to determine other causes of publication bias by examining the symmetry of the plot. Further, we did sensitivity analyses and cumulative meta-analysis by stepwise adding or omitting included studies. We also applied the trim-and-fill method to evaluate the effect of publication bias (72), and a filled forest plot was constructed to preclude the publication bias on pHR and pRR. The meta-analyses using a QE
model were performed using the MetaXL software to estimate the pHR and pRR. All the other data processing and statistical analysis were conducted by R software version 4.1.1. All the p-values were on two sides, and p-value <0.05 was considered with statistical significance.

RESULTS

A total of 1,239 publications were retrieved from electronic databases and gray literatures, and a total of 33 studies were selected and included in this systematic review and meta-analysis after employing exclusion criteria (Figure 1). A total of 473 duplicates were removed by automatic tools and artificial identification successively. A total of 650 records were excluded after reading the title and abstract, and 50 records were excluded for not having full-text or original data. After reading the full text, 31 records were excluded due to lack of data about BCR and two records were excluded because they did not belong to cohort studies (one RCT (73) and one case–control (74) study). Finally, 33 studies met the inclusion criteria for the current review. The inter-rater reliability between the two authors during the selection process was good (κ = 0.87).

Characteristics of Included Studies

The characteristics of all the 33 studies are presented in Table 1. All the studies were observational cohort studies published between 2006 and 2021. Twenty-four studies were conducted in the United States (35, 37, 40, 43–48, 51–54, 56–59, 61–67), two in South Korea (42, 60), one in Portugal (38), one in Greece (50), one in France (55), two in Finland (36, 41), and one in Canada (39), and one study collected data from six centers located in the North America and Europe (49). The study cohort size ranged from 247 (43) to 6,842 (49) among the included studies. The percentage of statin users ranged from 11.4% (45) to 70.4% (43). All the included studies had at least 2 years of median or mean follow-up duration. The primary treatment of patients for 18 studies was RP, including open, laparoscopic, or robot-assisted RP. Nine studies used RT (either external beam, brachytherapy, or a combination of them) as primary treatment. Three studies included patients treated with RP or RT. Two studies chose ADT as their primary treatment, and one study brought into patients treated with RP or RT or ADT. In some studies, patients

![Figure 1](https://example.com/fig1.png)
| Study | Year | Country | Follow-up period | Patient characteristics | Age (years), mean (SD) or median (IQR) | BMI (kg/m²), mean (SD) or median (IQR) | Cholesterol (mg/dL), mean (SD), or median (IQR) | Race PSA (ng/mL), mean (SD), or median (IQR) | Gleason score | Tumor stage | Primary treatment (s) | Definition of statin use | Definition of BCR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nicole Prabhut al. (35) | 2021 | USA | 2002–2015, median 112.8 months (IQR 70.68–149.7) | Patients from the National Cancer Institute-funded Specialized Program of Research Excellence (SPORE) | (1) μ: 72.8 (7.28); (2) μ: 71.0 (8.07) | | (1) T0: 0.2%; (2) T2b–T4: 59.3%; T3a–T4: 21.9% | (1) T0: 60.0%; (2) 0.2% | NR | RP | 2 years prior to or any time subsequent to RP | A detectable or rising PSA greater than or equal to 0.2 ng/mL | 3,088 | 1,222 (39.6%) | NR | 8 |
| A. I. Pettomaa et al. (36) | 2021 | Finland | 1996–2015, average 6.3 years (range 5.4–9.1) | Finnish randomized study of screening for prostate cancer in the metropolitan areas of Helsinki or Tampere | (1) M: 69.7; (2) M: 69.0 (23.7–29.7) | | (1) ≥7: 63.5%; (2) ≥7: 66.1% | (1) T1–T2: 70.0%; T3–T4: 30.0% | NR | ADT | After ADT initiation | Two consecutive rises of at least 50% from nadir PSA provided that the final PSA was over 2 | 4,428 | 2,544 (57.5%) | Adjusted by age, randomization group, medications, and PCa risk group | 9 |
| Linda My Huynhet al. (37) | 2021 | USA | 2007–2020, mean 3.4 years (range 0.7–6.1) | Patients from University of California, Irvine, and University of Nebraska Medical Center. Patients undergoing adjuvant therapies following RP and/or those without follow-up were excluded | (1) μ: 64.7 (7.2); (2) μ: 61.9 (7.0) | | (1) T1–T2: 96.7%; T3–T4: 4.3%; (2) T1–T2: 95.1%; T3–T4: 4.9% | (1) T1–T2: 0.2%; (2) T2b–T4: 59.3% | NR | RP or RT | Two consecutive PSA values >0.2 ng/mL in the radical prostatectomy cohort and 2 ng/mL PSA above nadir in the radiation therapy cohorts, respectively | Two consecutive PSA measurements >0.2 ng/mL after an undetectable PSA <0.1 ng/mL | 1,581 | 685 (43.3%) | NR | 8 |
| Roberto Jarimba et al. (38) | 2020 | Portugal | 2009–2018, mean 51.2 months (range 19.9–82.5) | Patients from Centro Hospitalar e Universitário de Coimbra | (1) μ: 64.43 (6.60); (2) μ: 62.95 (6.96) | | (1) T0: 63.9%; T3: 35.7%; (2) T2: 65.7%; T3: 34.3% | (1) T2: 8.83 (8.9) | NR | RP | All HMG-CoA reductase inhibitors (including combination therapies such as ezetimibe/simvastatin); patients used statins at the date of surgery and did not suspend the drug afterward | 702 | 400 (57.5%) | Adjusted for baseline demographic and clinical features | 8 |
| Study                  | Year     | Country | Follow-up period | Patient characteristics | Age (mean, median [SD] or median [IQR]) | BMI (kg/m², mean [SD] or median [IQR]) | Cholesterol (mg/dL, mean [SD] or median [IQR]) | Race PSA (ng/mL, mean [SD] or median [IQR]) | Gleason score | Tumor stage | Primary treatment(s) | Definition of statin use | Definition of BCR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|-----------------------|----------|---------|------------------|--------------------------|----------------------------------------|----------------------------------------|---------------------------------------------|---------------------------------------------|----------------|-------------|---------------------|--------------------------|----------------|----------------|-------------------------------|---------------------|-----|
| Viranda H. Jayalath et al. (39) | 2018 Canada | 1995–2016, median 50 months | Men at the Princess Margaret Cancer Center with low-risk prostate cancer at diagnosis (Gleason score <7, <4 positive cores, <50% involvement of any one core, and PSA <10.0 ng/dL), who had not undergone active treatment were eligible | (1) M: 65 (61–69); (2) M: 62 (57–67) | (1) <30: 76.5%; (2) <30: 80.8% | (1) 3.2, 6.5); (2) 4.9 (3.7, 6.4) | (1) M: 4.9 (3.2, 6.5); (2) M: 4.9 (3.7, 6.4) | (1) 0%; (2) ≥7: 0% | NR | RP or RT | A man was considered a statin user if one of the following criteria were fulfilled: (1) statin use was reported on the date of diagnosis; (2) dates for statin use encompassed the date of diagnosis; or (3) statin use was noted within 3 months after prostate cancer diagnosis. | PSA ≥0.2 ng/mL after RP, a PSA ≥2 ng/mL above the nadir after RT, or the initiation of salvage therapy | 291 | 67 | 23.0% | | 8 |
| Emma H. Allott et al. (40) | 2018 USA | 2008–2011, median 3.8 years | The North Carolina-Louisiana Prostate Cancer Project (PCaP) | (1) µ: 63.3 (7.0); (2) µ: 60.8 (7.8) | (1) <30: 53.3%; (2) <30: 66.8% | (1) 4.2–7.4); (2) M: 5.5 (4.3–8.3) | (1) M: 5.2 (4.2–7.4); (2) M: 5.5 (4.3–8.3) | (1) ≥7: 16%; (2) ≥7: 16% | NR | RP or RT | Research subjects gathered all prescription medications used in the 2-week period prior to interview and presented them to the research nurse at the time of interview for documentation of statin use. | Undetectable PSA after RP that was followed by a PSA ≥0.2 ng/mL, confirmed with a second PSA ≥0.2 ng/mL or nadir [lowest PSA achieved after radiation] + 2 ng/mL | 669 | 244 | (36.5%) | Adjusted for age, race, and obesity status | 7 | |
| Teemu Keskiövi et al. (41) | 2016 Finland | 1995–2009, median 8.6 years | Men who accepted prostate cancer treatment at the Tampere University Hospital (TAUH) | (1) M: 63; (2) M: 63 | (1) <4.8: 49.4%; (2) <4.8: 50.5% | (1) ≥7: 52.5%; (2) ≥7: 56.6% | (1) T1–2 N0/Mx: 99.2%; T3 and/or N1 and/or Mx: 0.8%; (2) T1–2 N0/Mx: 96.4%; T3 and/or N1 and/or Mx: 3.6% | (1) ≥7: 0%; (2) ≥7: 0% | RP | Two consecutive PSA values of 0.2 ng/mL or above or radiological progression after prostatectomy | | 1,314 | 528 | (40.2%) | Adjusted for age at surgery, tumor stage and Gleason grade, PSA level at the time of diagnosis, surgical margin positivity, total cholesterol, and use of antidiabetic and antihypertensive drugs | 8 | |
| Study                  | Year | Country | Follow-up period | Country | Study Year | Country | Follow-up period | Patient characteristics | Age (mean), mean (SD) or median (IQR) | BMI (kg/m²), mean (SD) or median (IQR) | Cholesterol (mg/dL), mean (SD), or median (IQR) | Race PSA (ng/mL), mean (SD), or median (IQR) | Gleason score | Tumor stage | Primary treatment (%) | Definition of statin use | Definition of BCR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|-----------------------|------|---------|-----------------|---------|-------------|---------|-----------------|-------------------------------|--------------------------------|--------------------------------|--------------------------------|-------------------|---------------|----------------|-----------------|-----------------|----------------|-----------------|-----------------|-----------------|
| Cheryn Song et al.   | 2015 | South Korea | 1998–2011, median 32 months (IQR: 18.2–55.2) | South Korea | 2015 | South Korea | 1998–2011, median 32 months (IQR: 18.2–55.2) | Korean patients with prostate cancer who had undergone RP at Asan Medical Center | (1) M: 67 (63, 70); (2) M: 67 (63, 71) | (1) M: 25.2 (23.4, 27.5); (2) M: 24.4 (22.6, 26.4) | (1) M: 179 (159, 201); (2) M: 166 (143, 199) | (1) M: 6.2 (4.5, 9.6); (2) M: 6.9 (4.7, 11.2) | NR | Preoperative statin use from each patient’s medical record; postoperative statin use was evaluated through telephone survey | Preoperative statin use from each patient’s medical record; postoperative statin use was evaluated through telephone survey | Yes | 2137 | 452 (21.2%) |
| Daniel S. Oh et al.  | 2015 | USA | 1999–2009, 51 months (range 9.4–140.35) | USA | 2015 | USA | 1999–2009, 51 months (range 9.4–140.35) | Men with prostate cancer treated at the Durham Veterans affairs Medical center | (1) M: 62.8; (2) M: 61.4 | NR | NR | (1) M: 31.6% for white, 26.3% for AA; (2) 36.4% for white | (1) M: 7.2; (2) M: 6.05 | (1) M: 25.2 (23.4, 27.5); (2) M: 24.4 (22.6, 26.4) | (1) T1–T2a: 97%; (2) T2b–c: 3%; T3–4: 0%; (2) T1–T2a: 92%; T2b–c: 7%; T3–4: 1%; (1) T1–T2a: 79%; T2b–c: 18%; T3a–b: 3%; (2) T1–T2a: 75%; T2b–c: 19%; T3a–b: 6%; (1) T1–T2a: 98.0%; T3–T4: 2.0%; (2) T1–T2a: 96.5%; T3–T4: 3.5% | Rise of 2 ng/mL or more above the nadir after RT | Yes | 247 | 174 (70.4%) |
| John Cuaron et al.   | 2015 | USA | 1998–2010, 48 months (range 1–156) | USA | 2015 | USA | 1998–2010, 48 months (range 1–156) | Patients with clinically localized prostate cancer at Memorial Sloan Kettering Cancer Center | (1) ≥65: 74%; (2) ≥65: 73% | NR | NR | (1) M: 31.6% for white, 26.3% for AA; (2) 36.4% for white | (1) M: 7.2; (2) M: 6.05 | (1) M: 25.2 (23.4, 27.5); (2) M: 24.4 (22.6, 26.4) | (1) T1–T2a: 79%; T2b–c: 18%; T3a–b: 3%; (2) T1–T2a: 75%; T2b–c: 19%; T3a–b: 6%; (1) T1–T2a: 98.0%; T3–T4: 2.0%; (2) T1–T2a: 96.5%; T3–T4: 3.5% | Take a statin medication (statin group) before initiating RT | Yes | 754 | 273 (36.2%) |
| MR Danzig et al.     | 2015 | USA | 1995–2012, median 27 months | USA | 2015 | USA | 1995–2012, median 27 months | Diabetic patients in Columbia Urologic Oncology database, those accepting adjuvant radiation or hormonal therapy were excluded | (1) M: 65; (2) M: 63 | NR | NR | (1) M: 31.6% for white, 26.3% for AA; (2) 36.4% for white | (1) M: 5.72; (2) M: 6.05 | (1) M: 25.2 (23.4, 27.5); (2) M: 24.4 (22.6, 26.4) | (1) T1–T2a: 98.0%; T3–T4: 2.0%; (2) T1–T2a: 96.5%; T3–T4: 3.5% | The first recorded PSA of more than 0.2 ng/mL | Yes | 669 | 76 (11.4%) |

(Continued)
| Study       | Year | Country | Follow-up period | Patient characteristics                                                                 | Age (mean), mean (SD or median [IQR]) | BMI (kg/m²), mean (SD or median [IQR]) | Cholesterol (mg/dL), mean (SD), or median (IQR) | Race | PSA (ng/mL), mean (SD), median (IQR) | Gleason score | Tumor stage | Primary treatment(s) | Definition of statin use | Definition of BCR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|------------|------|---------|------------------|----------------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|-----------------------------------------------|------|------------------------------------|-----------------|--------------|---------------------|------------------------|-----------------|------------------|------------------------|-------------------------|-----|
| Lauren C. Harshman et al. (46) | 2015 | USA    | 1996–2013, median 5.8 months (SD = 54.3) | Patients with hormone-sensitive PC from Dana-Farber Cancer Institute | (1) M: 62 (56, 67); (2) M: 60 (55, 66) | (2) 93.0% for white, 4% for AA; (1) 93.0% for white, 5% for AA | (1) M: 9.1 (8, 17); (2) M: 11.8 (8, 40) | (1) >7: 72%; (2) >7: 74% | (1) T1= T2: 76%; T3= T4: 4%; (1) T1= T2: 67%; T3-T4: 6% | ADT | Patients were defined as statin users if they were using statins at the time of ADT initiation | A minimum of 2 increases in PSA level | 926 | 283 | 90.6% | Adjusted for predefined prognostic clinical factors including biopsy Gleason score, type of primary therapy, use of prior ADT in conjunction with localized therapy, metastatic status, and PSA level at initiation of ADT | 7 |
| Miriam B. Ishak-Howard et al. (47) | 2014 | USA    | 1999–2009, median 54.9 months (SD = 56.6) | Study subjects came from the University of Michigan Prostate Cancer Genetic Project (PCGP) | (1) µ: 58.0 (7.4); (2) µ: 55.2 (7.6) | (1) <30: 82.1%; (2) <30: 85.6% | (1) µ: 7.9 (10.2); (2) µ: 7.1 (9.1) | (1) >7: 50.4%; (2) >7: 51.3% | (1) T2: 65.9%; T3: 10.9%; (2) T2: 70.4%; T3: 21.0% | RP | Any statin use over the last 10 years | A single PSA test value of ≥0.4 ng/mL following an undetectable PSA (<0.1 ng/mL) after RP | 539 | 258 | 47.9% | Adjusted for age at time of surgery, BMI, NSAID use, Gleason grade, pre-diagnostic PSA, clinical stage, and decade of surgery | 7 |
| Emma H. Allott et al. (48) | 2014 | USA    | 1996–2009, median 76.2 months (SD = 56.6) | Patients undergoing RP in Shared Equal Access Regional Cancer Hospital (SEARCH) Database, not including patients treated with preoperative ADT or RT | (1) µ: 60.6 (6.3); (2) µ: 60.7 (6.5) | (2) 97.5% for white, 2.1% for AA | (1) M: 202 (181–224); (2) M: 217 (243–301) | (1) µ: 5.9 (4.7, 9.1); (2) µ: 7.1 (5.1, 10.7) | (1) >7: 29%; (2) >7: 40% | (1) T1: 61%; T2/T3: 30%; T2/T3: 36% | RP | Postoperative statin use | A single PSA >0.2 ng/mL, two consecutive concentrations at 0.2 ng/mL, or secondary treatment for detectable postoperative PSA | 1,146 | 400 | 34.9% | Adjusted for age, race, PSA, BMI, pathological Gleason score, year of surgery, positive surgical margins, extracapsular extension, seminal vesicle invasion, lymph node involvement and center | 7 |
| M Reiken et al. (49) | 2013 | Multi- | 2000–2011, median 25.8 months (SD = 8.7) | patients with clinically localized PC treated with RP from six North American and European centers, not including patients treated with preoperative RT, hormonal treatment or chemotherapy | (1) µ: 61.7 (8.5); (2) µ: 61.0 (8.7) | (2) 34.5% for white, 65.5% for AA | (1) µ: 7.7 (5.5); (2) µ: 7.5 (6.0) | (1) >7: 43.5%; (2) >7: 45.8% | (1) T3: 25.3%; (2) T3: 25.3%; N1: 10.9%; N1: 11.4% | RP | Statin use at the time of diagnosis, regardless of statin type, dose, or cumulative exposure | PSA value >0.2 ng/mL on two consecutive visits | 6,842 | 2,275 | 33.3% | Adjusted for statin use, age (continuous), preoperative PSA (continuous), RP Gleason score, positive lymph nodes, positive surgical margins, stage T3a, stage T3b | 9 |

(Continued)
TABLE 1 | Continued

| Study                  | Year Country | Follow-up period | Patient characteristics | Age (mean), years (SD or median) | BMI (kg/m²), mean (SD or median) | Cholesterol (mg/dL), mean (SD or median) | PSA (ng/mL), mean (SD or median) | Gleason score | Tumor stage | Primary treatment (%) | Definition of statin use | Definition of BGR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|------------------------|--------------|-----------------|-------------------------|---------------------------------|----------------------------------|--------------------------------------|----------------------------------|----------------|-------------|------------------------|------------------------|----------------------|----------------|-----------------------------|------------------------|-----|
| M. Koniaros et al. (50) | 2013 Greece  | 1999–2010, mean 3.6 years | Patients without any antiandrogen or SARI medication; prepromptively from Siyanoglio Hospital of Attiki and Germenis General Hospital of Athens | (1) μ: 65.4 (5.5); (2) μ: 65.2 (5.0) | (1) μ: <25 (0.25); (2) μ: >25 (0.26) | (1) μ: 7.2 (6.6, 9.7); (2) μ: 8.0 (6.1, 10.6) | (1) μ: 20.6% (0.16); (2) μ: 26.0% | NR | NR | RP (cT1c: 70.1%; cT2: 29.9%); RP or RT (cT1c: 69.6%; cT2: 30.4%) | Any statin use preoperatively or postoperatively | NR | 588 | 170 (28.9%) | Adjusted for race, age, stage, positive surgical margins, and statin use | 6 |
| Milan S. Geybel et al. (51) | 2013 USA     | 2002–2005, mean 6.1 years | PCA patients aged 35–74 at diagnosis from a population-based, case–control study of PCAs via the SEER Program cancer registry | (1) μ: 63.1 (6.6); (2) μ: 60.9 (8.1) | (1) μ: <25 (2.0); (2) μ: >25 (8.5) | (1) μ: 5.7 (4.4, 6.5); (2) μ: 6.3 (4.7, 9.5) | (1) μ: 47.1% (0.47); (2) μ: 47.1% | NR | NR | RP or RT or ADT (cT1c: 97.5%; cT2: 98.7%); Stage II: 97.5%; Stage III: 98.7% | Users were defined as men who reported having taken a statin at least once a week for 3 months or longer | A posttreatment PSA value of 0.2 ng/mL or greater in men who underwent RP; nadir PSA level +2 ng/mL (Phoenix criteria), for men treated with RT; or any PSA increase in men treated with primary ADT | 685 | 208 (30.4%) | Adjusted for age at diagnosis (years), Gleason score, stage at diagnosis, diagnostic PSA level, primary treatment approach, race, first-degree family history of PCAs, body mass index, smoking status, lifetime alcohol consumption, aspirin use, non-aspirin NSAID use, history of diabetes mellitus, and history of PCa screening | 7 |
| Chun Chao et al. (52) | 2013 USA     | 2004–2011, mean 4.1 years | Patients ≥40 years who were diagnosed with incident prostate cancer in Kaiser Northern California, those with stage IV disease or unknown stage and received RP prior to RT were excluded | (1) μ: 69.3 (5.9); (2) μ: 67.5 (8.0) | (1) μ: <30 (6.7); (2) μ: <30 (7.8) | (1) μ: 6.2 (6.7, 7.8); (2) μ: 6.7 (7.9) | (1) μ: 52.1% (0.52); (2) μ: 49.6% | NR | NR | Stage II: 95.0%; stage III: 96.7% | Statin use prior to RT procedures | A rise in PSA by 2 ng/mL or more above the nadir PSA after radiation therapy based on the 2005 Phoenix definition | 774 | 401 (51.8%) | Adjusted for race, stage, Gleason score, prostate volume, PSA doubling time, advanced PSA velocity, Gleason score, and time from prostate cancer diagnosis to RT (continuous) | 7 |
| Chun Chao et al. (53) | 2013 USA     | 2004–2010, mean 4.3 years | All men aged 40 years and older with incident prostate cancer in the Kaiser Northern California | (1) μ: 61.0 (6.6); (2) μ: 59.0 (7.0) | (1) μ: >30 (4.2); (2) μ: <30 (6.4) | (1) μ: 6.7 (4.4, 7.1); (2) μ: 6.7 (6.4) | (1) μ: 48% (0.48); (2) μ: 44% | NR | NR | Stage II: 85%; stage III: 15%; stage IV: 1.3% | Statin use prior to prostatectomy from KPSC’s electronic pharmacy records | A single PSA level >0.2 ng/mL after an undetectable PSA measurement | 1,184 | 446 (37.7%) | Adjusted for age, race, stage, Gleason score, preoperative PSA, time from prostate cancer diagnosis to RT (continuous) | 7 |

Continued
| Study | Year | Country | Follow-up period | Patient characteristics | Age (years), mean (SD) or median (IQR) | BMI (kg/m²), mean (SD) or median (IQR) | Cholesterol (mg/dL), mean (SD), or median (IQR) | Race | PSA (ng/mL), mean (SD), or median (IQR) | Gleason score | Tumor stage | Primary treatment(s) | Definition of statin use | Definition of BCR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|-------|------|---------|------------------|--------------------------|----------------------------------------|----------------------------------------|---------------------------------|------|------------------------------------------|----------------|-------------|------------------|----------------|-----------------|---------------------|-----------------|--------------------------|---------------|------|
| Alon Y. Mass et al. (54) | 2012 USA | 2000–2008, median 57 months | Patients with clinically localized PCa at New York University (KPSC); those with stage IV disease or received neoadjuvant therapy prior to RP were excluded | NR | (1) M: 64 (61, 70); (2) M: 64 (59, 60) | (1) M: 5.1 (4.0, 6.8); (2) M: 5.0 (4.0, 7.0) | NR | (1) M: 6.6 (4.8, 8.1); (2) M: 6.4 (4.7, 8.8) | (1) 7: 72.1%; (2) 7: 77.1% | (1) T1c: 67%; T2: 31%; T3: 2%; (2) T1c: 71%; T2: 26%; T3: 1% | RT | Stain drugs included atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin | PSA greater than 0.2 ng/ml with a confirmatory reading above this threshold | 1,446 | 437 (30.2%) | Adjusted for age at diagnosis, preoperative PSA, pathological tumor stage, postoperative pathological Gleason score, and race | 8 |
| V. Misrai et al. (55) | 2012 France | 2004–2008, mean 33 months (SD = 10) | Men with clinical stage T1–4, N0/X, M0 adenocarcinoma of the prostate without ADT | NR | (1) M: 69 (36, 88) | (1) M: 7.1; (2) M: 6.1; (3) M: 6.0 | NR | >10: 30%; ≥7: 26% | (1) T1: 58%; T2: 39%; T3: 3% | RT | Data on statin use were extracted from the admission or discharge records of patients at the time of RP | PSA ≥0.2 ng/ml after surgery | 377 | 97 (25.7%) | Adjustment for the D'Amico group criterion and the other confounding factors (type 2 diabetes and positive surgical margins) | 6 |
| Nicholas G Zaorsky et al. (56) | 2012 USA | 1986–2006, median 75 months (range: 18–239) | Patients from the Columbia University Comprehensive Urologic Oncology Database, and patients were excluded from the analysis if they had (1) <2 years of adequate follow-up, (2) neo-adjuvant or adjuvant therapy in the form of hormones, (3) those with stage IV disease or received neoadjuvant therapy prior to RP were excluded | NR | (1) M: 69 (36, 88) | (1) M: 6.9 (4.8, 8.1); (2) M: 6.4 (4.7, 8.8) | NR | M: 7.1; (2) M: 7.1 | (1) T1: 58%; T2: 39%; T3: 3% | RT | Stain drugs included atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin | Nadir + 2 ng/ml on two successive dosages postoperatively | 2,045 | 689 (33.7%) | | 7 |
| Chad R. Ritch et al. (57) | 2011 USA | 1990–2008, median 36 months | Patients from the Uro-Oncology Database at Memorial Sloan-Kettering Cancer Center, and patients were excluded from the analysis if they had (1) <2 years of adequate follow-up, (2) neo-adjuvant or adjuvant therapy in the form of hormones, (3) those with stage IV disease or received neoadjuvant therapy prior to RP were excluded | NR | (1) M: 69 (36, 88) | (1) M: 6.4 (4.0, 7.0) | NR | M: 7.1; (2) M: 7.1 | (1) T1: 58%; T2: 39%; T3: 3% | RT | Data on statin use were extracted from the admission or discharge records of patients at the time of RP | PSA ≥0.2 ng/ml after a previously undetectable PSA 3 months postoperatively | 1261 | 281 (22.3%) | | 7 |
### TABLE 1 | Continued

| Study | Year | Country | Follow-up period | Patient characteristics | Age (mean), mean (SD) or median (IQR) | BMI (kg/m²), mean (SD) or median (IQR) | Cholesterol (mg/dL), mean (SD), or median (IQR) | Race | PSA (ng/mL), mean (SD), or median (IQR) | Gleason score | Tumor stage | Primary treatment (%) | Definition of statin use | Definition of BGR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|-------|------|---------|------------------|-------------------------|---------------------------------------|----------------------------------------|-------------------------------------------|------|--------------------------------------|-----------------|----------------|------------------------|----------------------------|----------------|----------------|-------------------------------|------------------|---|
| Alison M. Mondul et al. (59) | 2011 | USA | 1993–2006; median 7 years | Patients with clinically localized prostate cancer at the Johns Hopkins Hospital, those who received hormone or RT before prostatectomy were excluded | (1) µ: 57.7; (2) µ: 56.0 | NR | (1) µ: 26.7; (2) µ: 26.3 | NR | (1) <30: 74%; (2) ≤7: 73% | NR | NR | RP | Statin use starting before or after surgery | A confirmed repeat PSA increase from a nadir of nondetectable to 0.2 ng/mL or greater | 1,583 | 779 | (49.2%) | Adjusted for age, race, BMI, smoking, prostate cancer family history, aspirin use, and ACE inhibitor use at prostatectomy, surgery calendar year, preoperative PSA, pathological stage, and Gleason sum | 8 |
| Marisa A Kollmeier et al. (59) | 2011 | USA | 1995–2007; median 5.9 years (range: 0–14 years; IQR: 3.5–10.5 years) | Patients treated at Memorial Sloan-Kettering Cancer Center for clinically localized stage T1–T3 prostate adenocarcinoma | (1) ≤65: 74%; (2) ≤65: 73% | NR | NR | (1) <30: 74%; (1) >10: 27%; (2) >10: 29% | (1) 57%; (2) 52%; (3) 55% | (1) T1: 73.7%; (2) T2–T3a: 26.3%; (3) T2–T3a: 32.1% | RT | All HMG-CoA reductase inhibitors according to medical record review | Nadir +2 definition | 1,681 | 382 | (22.7%) | NR | 7 |
| JH Ku et al. (60) | 2011 | South Korea | 1997–2008; median 38 months (range: 3–143 months) | Patients who underwent retropubic RP and who did not receive neoadjuvant treatment at Seoul National University Hospital | (1) µ: 65.3; (2) µ: 65.2 | NR | NR | (1) µ: 9.6; (2) µ: 13.6 | (1) >7: 52.5% | (1) T1: 58%; (2) T2: 37%; T3: 7%; (3) T2: 48%; T2: 40%; T3: 12% | RP | All 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors | A single PSA of 0.2 ng/mL or greater with another increasing value | 609 | 70 | (13.0%) | NR | 8 |
| Robert J. Hamilton et al. (61) | 2010 | USA | 1988–2008; median 38 months (IQR: 13–68 months) | for non-statin users, median 24 months (IQR: 11–52) | for non-statin users | NR | NR | (1) M: 6.2; (2) M: 6.9 | (1) >7: 52%; (2) >7: 38% | (1) T1c: 67%; T2–T3a: 33%; (2) T1c: 58%; T2–T3a: 42% | RP | Statin use at surgery | A single PSA of 0.2 ng/mL or secondary treatment for detectable postoperative PSA | 1,319 | 236 | (17.9%) | Adjusted for clinical and pathological characteristics: pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margins, and lymph node metastases | 7 | (Continued) |
| Study            | Year  | Country | Follow-up period | Patient characteristics | Age (mean, SD) or median (IQR) | BMI (kg/m²), mean (SD) or median (IQR) | Cholesterol (mg/dL), mean (SD) or median (IQR) | Race PSA (ng/mL), mean (SD) or median (IQR) | Gleason score | Tumor stage | Primary treatment(s) | Definition of statin use | Definition of BCR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|------------------|-------|---------|------------------|--------------------------|---------------------------------|--------------------------------------|---------------------------------------------|-----------------------------------------------|----------------|-------------|----------------------|----------------------|----------------|----------------|-------------------------------|----------------------|-----|
| L. Spencer Krane et al. (62) | 2010 USA | 2001–2008, mean 26 months | Men with biopsy proven prostate cancer at the Vattikuti Urology Institute | (1) M: 61.4 (6.6); (2) M: 59.4 (7.5) | (1) M: 28 (26, 30); (2) M: <30: 67.7% (30, 30) | (1) M: 5.0 (4.1, 6.6); (2) M: 5.2 (4.1, 7.2) | (1) ≥7: 69%; (2) ≥7: 64% | (1) T1c: 73; T2: 27%; T3: 27% | RP | No. of patients on statins | Single PSA of 0.2 ng/mL or greater with another increasing value | NR | 3,828 | 1,031 | (26.9%) | 7 |
| Jorge Roja et al. (63) | 2010 USA | 2003–2009 | Patients were treated at Memorial Sloan-Kettering Cancer Center | (1) M: 62 (57, 66); (2) M: 59 (54, 64) | (1) M: 186 (104, 315); (2) M: 192 (92, 292) | (1) ≥7: 76%; (2) ≥7: 72.1% | (1) M: 5.1 (3.8, 7.0); (2) M: 5.3 (3.9, 7.5) | (1) ≥7: 76%; (2) ≥7: 71% | No. of patients on statins | We ascertained statin use from a prospective database | NR | 3,748 | 1,084 | (27.7%) | 7 |
| Ruchika Gutt et al. (64) | 2010 USA | 1988–2006, median 50 months | Patients were treated at the University of Chicago Pritzker School of Medicine for nonmetastatic prostate adenocarcinoma, those with prior prostatectomy were excluded | (1) M: 69 (42, 83); (2) M: 68 (44, 83) | (1) 48% for white, 49% for AA; (2) 42% for white, 53% for AA | (1) >10: 43%; (2) ≥4: 37% | (1) T1–2a: 88%; T2b–c: 9%; T3: 7%; T4: 3%; (2) T1–2a: 79%; T2b–c: 15%; T3: 7%; T4: 7% | (1) M: 1.0 (0.2, 12.0); (2) M: 4.6 (0.2, 17.2) | (1) ≥7: 64% | RP | Statin therapy during RT or during follow-up | The Phoenix definition (PSA nadir + 2 ng/ml) | NR | 691 | 189 | (27.4%) | 8 |
| Daniel E. Soto et al. (65) | 2009 USA | 1987–2006, median 47 months (range 2.5 months to 16.5 years) | Patients with localized prostate cancer who were treated at the University of Michigan Cancer Center, exclusion criteria included the presence of known lymphatic metastases, nonpneumatic metastatic disease, the use of neoadjuvant or adjuvant chemotherapy, and a history of prostatectomy, cryosurgery, or brachytherapy | (1) M: 68.0 (7.2); (2) M: 68.2 (7.3) | (1) ≥7: 75%; (2) ≥7: 71% | (1) T1c: 73; T2: 27%; T3: 27% | (1) M: 3.1 (0.2, 12.0); (2) M: 4.6 (0.2, 17.2) | (1) ≥7: 59.9% | (1) ≥7: 64% | RT | Statin use before the start of RT | Phoenix definition of a current PSA nadir + 2 ng/ml or the initiation of salvage ADT | NR | 968 | 220 | (22.7%) | 7 |
TABLE 1 | Continued

| Study          | Year | Country | Follow-up period | Characteristic(s)          | Age (mean, SD or median [IQR]) | BMI (kg/m²), mean (SD) or median (IQR) | Cholesterol (mg/dL), mean (SD) or median (IQR) | Race PSA (ng/mL), mean (SD) or median (IQR) | Gleason score | Tumor stage | Primary treatment(s) | Definition of BCR | No. of patients | No. of patients on statins (%) | Covariate adjustment | NOS |
|----------------|------|---------|------------------|-----------------------------|-------------------------------|-------------------------------------|---------------------------------------------|---------------------------------------------|----------------|-------------|---------------------|-------------------|-----------------|-----------------------------|-------------------|-----|
| A.M. Shippy et al. (69) | 2007 | USA     | 1995–2000, median 85 months | Men with clinical stage T1a–T3 prostate adenocarcinoma at Memorial Sloan-Kettering Cancer Center | NR | NR | NR | NR | NR | NR | RT | According to the nadir ≥ 2 ng/ml (Phoenix) criteria | 871 | 168 (19.3%) | NR | 4 |
| N.K. Sharma et al. (67) | 2006 | USA     | 1995–2000, median 56.1 months | Patients from Fox Chase Cancer Center; those who received ADT were excluded | M: 69 (43.84) | NR | NR | M: 7.4 | ≥7: 31% | T1–T2: 90%; T3–T4: 3.5% | RT | Statin use before, during and after RT | 983 | 178 (18.1%) | Age (continuous), dose (continuous), Gleason score, PSA (continuous), stage | 6 | 1 |

RT, radiation therapy; RP, radical prostatectomy; ADT, androgen deprivation therapy; BCR, biochemical recurrence; BMI, body mass index; IQR, interquartile range; SD, standard deviation; USA, United States of America; AA: African American; NOS, Newcastle-Ottawa scale; NR, not reported.

(1) denotes statin users and (2) non-statin users.

*Including five Veterans Administration (VA) Medical Centers (Palo Alto, CA; West Los Angeles, CA; Durham, NC; Asheville, NC; Augusta, GA).

*Including Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University of Montreal, Montreal, QC, Canada; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy; Prostate Cancer Center, Hospital Barmherzige Schwestern Linz, Linz, Austria; Department of Urology, Medical University of Graz, Graz, Austria.

Statin Use and the HR and RR of BCR

The HR of BCR was reported in 15 included studies. As shown in the forest plots, statin users were significantly less likely to experience an event (BCR) than non-users (66, 67). However, the type, dose, or duration of statin use was various in different studies. Patients were considered as statin users if they had ever used statins of any type or any dose at any time recorded in the medication database. The majority of studies restricted the duration of statin use such as statin use longer than 10 years (35, 47, 51).

The definition of the BCR in most studies were the same: a posttreatment PSA value of 0.2 ng/ml or greater for men who underwent RP or RT; any PSA increase in men treated with ADT; and no evidence of clinical and/or radiographic detected disease. However, the definition of clinical and/or radiographic detected disease was various in different studies. Patients were considered as statin users if they had ever used statins of any type or any dose at any time recorded in the medication database. In many studies, statin use was defined as some dose. For example, five studies recorded the dose of statin use (45, 50, 61, 63). Three studies restricted the duration of statin use such as statin use longer than 10 years (35, 47, 51).
TABLE 2 | Newcastle–Ottawa Scale for assessing the quality of studies in meta-analysis.

| Study                          | Selection Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of the study | Comparability Comparability of cohorts on the basis of the design or analysis | Outcome Was followed up long enough for outcomes to occur | Adequacy of follow-up of cohorts | Score |
|-------------------------------|--------------------------------------------------|-------------------------------------|---------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------|-------|
| Nicole Prabhu et al, (35)    | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆☆                                                                              | ☆                                                                               | ☆                               | 8     |
| A. I. Peltomaa et al, (36)    | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆☆                                                                              | ☆                                                                               | ☆                               | 9     |
| Linda My Huynh et al, (37)    | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆☆                                                                              | ☆                                                                               | ☆                               | 8     |
| Roberto Jarimba et al, (38)   | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 8     |
| Viranda H. Jayalath et al, (39)| ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 8     |
| Emma H. Allott et al, (40)    | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| Teemu Keskivali et al, (41)   | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 8     |
| Cheryn Song et al, (42)       | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| Daniel S. Oh et al, (43)      | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| John Quaron et al, (44)       | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| MR Danzig et al, (45)         | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 6     |
| Lauren C. Harshman et al, (46)| ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| Miriam B. Ishak-Howard et al, (47)| ☆                                             | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| Emma H. Allott et al, (75)    | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| M Rieken et al, (49)          | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 9     |
| M. Kontraros et al, (50)      | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 6     |
| Milan S. Gaybelis et al, (51) | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| Chun Chao et al, (52) (RT)    | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |
| Chun Chao et al, (53) (RP)    | ☆                                                | ☆                                   | ☆                         | ☆                                                                           | ☆                                                                               | ☆                                                                               | ☆                               | 7     |

(Continued)
experience the BCR of prostate cancer after primary treatment, with a pHR of 0.86 (95% CI: 0.78 to 0.95, I² = 64%, random effects model, Figure 2A) and a pRR of 0.74 (95% CI: 0.57 to 0.94, 24591 patients, I² = 88%, random effects model, Figure 2B).

Subgroup analyses according to primary treatment for HR showed that there still existed significant BCR reduction among patients accepting RT (pHR: 0.78, 95% CI: 0.61 to 0.98, I² = 57%, random effects model, Figure 3) or ADT (pHR: 0.76, 95% CI: 0.68 to 0.86, I² = 27%, random effects model, Figure 3) as their primary treatment, which was consistent with previously published articles (33, 76). However, as for RR, the subgroup analyses according to primary treatment exhibited that there just existed a significant difference in patients accepting ADT but only one study was divided into this group (Figure S1A).

Subgroup analyses according to country for both RR (Figure S1B) and HR (Figure S1C) showed that statin use was significantly associated with BCR reduction in patients from USA.

As the heterogeneity was high in both the main analysis and subgroup analyses, we then performed meta-regression to find out the covariates causing this variability. We used publication year, follow-up duration, age, BMI value, the percentage of BMI <30 kg/m², serum cholesterol level, the percentage of AA, serum PSA level, GS, and stage to construct the univariate meta-regression model. For HR, we found that the serum cholesterol level was significantly associated with BCR (p = 0.0074, Figure 4A). As for RR, there existed a remarkable connection between GS and BCR (p = 0.0448, Figure 4B). However, we did not find a significant

### TABLE 2 | Continued

| Study | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of the study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Was followed up long enough for outcomes to occur | Adequacy of follow-up of cohorts | Score |
|-------|----------------------------------------|-----------------------------------|--------------------------|-------------------------------------------------|-------------------------------------------------|--------------------|---------------------------------|---------------------------------|-------|
| Alon Y. Mass et al, (54) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| V. Misrai et al, (55) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 6 |
| Nicholas G Zaorsky et al, (56) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 7 |
| Chad R. Ritch et al, (57) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 7 |
| Alison M. Mondul et al, (58) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| Marisa A Kolmeier et al, (59) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 7 |
| JH Ku et al, (60) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| Robert J. Hamilton et al, (61) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 7 |
| L. Spencer Krane et al, (62) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 7 |
| Jorge Rioja et al, (63) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 7 |
| Ruchika Gutt et al, (64) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 8 |
| Daniel E. Soto et al, (65) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 7 |
| A. M. Shippy et al, (66) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 4 |
| N. K. Sharma et al, (67) | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | ☆ | 6 |

A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.
association between publication year, follow-up duration, age, BMI value, the percentage of BMI <30 kg/m², the percentage of AA, serum PSA level, GS or stage, and BCR in HR (Figures S2A–I, Table S2), and publication year, follow-up duration, age, BMI value, the percentage of BMI <30 kg/m², the percentage of AA, serum PSA level or stage, and BCR in RR (Figures S3A–H, Table S3).

Then we conducted sensitivity analysis and cumulative meta-analysis by sequentially omitting or adding each study in turn to evaluate its effect on the pHR or pRR. For HR, we could observe that the overall estimates remained stable after omitting (Figure 5A) and adding (Figure 5B) each study. Moreover, we did not detect a statistically significant bias based on Beggs’s test (z = -1.22, p = 0.2210) and Egger’s test (t = -0.27, p = 0.7897). Besides, the contour-enhanced funnel plot also showed good symmetry of the plot (Figure 5C). The trim-and-fill method suggested little evidence of publication bias (Figure 5D) and estimated that two studies were missing resulting from publication bias (Figure 5E). After filling the two missing studies, the filled forest plot also showed a significant reduction in BCR among statin users with a pHR of 0.88 (95% CI: 0.79 to 0.97, I² = 66%, random effects model), which was in accordance with the original model. As shown in Figure 5F, the Galbraith plot also exhibited a low publication bias with most studies located between the dashed lines. As for RR, we could observe a significant change in the pooled effect when omitting or adding three studies including Oh et al., Allott et al., and Zaorsky et al. (43, 48, 56) (Figure S4A, B). The contour-enhanced funnel plot also did not show good symmetry of the plot visually with most studies lying outside of the dashed lines.

**FIGURE 2** | The effect of statins on BCR risk of prostate cancer among men following definitive therapy using the random effects model. (A) Forest plot for the HR of BCR. (B) Forest plot for the RR of BCR.
However, we did not identify a statistically significant publication bias based on Begg’s test (z = -1.14, p = 0.2550) and Egger’s test (t = -1.17, p = 0.2639). In contrast, the trim-and-fill method supported the result of the contour-enhanced funnel plot (Figure S4D) and estimated that two studies were missing resulting from publication bias (Figure S4E). After filling the two missing studies, the pooled effect lost statistical significance with a pHR of 0.83 (95% CI: 0.62 to 1.11, I² = 90%, random effects model), which indicated that the publication bias might have influenced the original outcome.

The Galbraith plot also exhibited a relatively high publication bias with almost half of the studies outside between the dashed lines (Figure S4F). Nevertheless, the L’Abbé plot showed that included studies generally agreed on the positive effect of statins in reducing the RR of BCR (Figure S4G).

Considering the quality of the included studies, we also performed meta-analyses using a QE model using the MetaXL software. As shown in Figure 6A, for HR, there still existed a significant reduction in BCR among statin users with study quality taken into consideration (pHR: 0.84, 95% CI: 0.75 to 0.95, I² = 64%, quality effects model). However, as for RR, the result lost statistical significance when using the QE model (pHR: 0.83, 95% CI: 0.62 to 1.12, I² = 88%, quality effects model, Figure 6B), which revealed that there existed a remarkable heterogeneity in the quality of included studies on the RR of BCR.

**DISCUSSION**

The aim of our study was to reevaluate the association between statin use and the risk of BCR among patients with PCa after definite treatment. This review comprised 33 cohort studies, including 31 studies reporting the HR of BCR and 15 studies...
reporting the RR of BCR. We found that statin use was tightly connected with the reduction of BCR among patients with PCa, especially for those accepting RT as their primary treatment, which was consistent with previously published meta-analyses (33, 76). Although patients in the subgroup accepting ADT also showed a significant reduction in HR of BCR, the number of studies in this subgroup was too limited and part of the patients have also accepted other treatments except ADT in these studies, which could bring bias into the final results. Although five studies have reported a remarkable effect of statins on the reduction of BCR after RP, the pooled effect showed no statistical significance due to the heterogeneity of included studies. An RCT study published by Jeong et al. in 2021 showed that 20 mg/day of atorvastatin use for 24 months had no significant effect on the risk of BCR in patients with high-grade prostate cancer after RP (HR, 1.00; 95% CI, 0.71–1.41), which was in accordance with our conclusion. The reason why statins could reduce the risk of BCR could be that statin might improve the radiosensitivity of prostate cancer by causing cell-cycle arrest in the late G1 phase (77). Statins could induce late G1 arrest and apoptosis by inhibition of cdk2, E2F1, p21, and/or p27 (78). A recent study showed that statins could also enhance the effects of RT by triggering the interaction between Bcl-2 and MSH2 (79) and compromising DNA double-strand breaks repair (80). The development and progression of PCa were dependent on androgens, and cholesterol is a precursor for androgen synthesis. Therefore, cholesterol lowering by statins could suppress androgen synthesis and enhance the efficacy of ADT treatment. It was also reported that statins could compete with androgens for influx by the SLCO2B1 transporter, thus decreasing tumor’s androgen supply (81). In vitro studies have also discovered that statins could increase the therapeutic effect of abiraterone acetate and enzalutamide (82). Further studies are needed, and more clinical trials should be carried out to verify the hypotheses.

Previous epidemiological observations and preclinical models suggested that hypercholesterolemia might play a crucial role in the incidence and progression of PCa, especially in increasing the risk of high-grade, aggressive disease and castration resistance (83, 84). It was also reported that elevated cholesterol was associated with increased risk of recurrence among men with dyslipidemia after RP (75). In our study, using meta-regression, we found that serum cholesterol level was a significant confounder which could neutralize the protective effect of statins on BCR, which indicated that statins might reduce the risk of BCR by mediating hypercholesterolemia. A recent study has found that sterol-O-acyl transferases (SOAT) 1, an enzyme involved in cholesteryl ester synthesis, was remarkably connected to earlier BCR in high-risk prostate cancer (85). However, Lefebvre et al. observed that there existed no significant association between metabolic syndrome including hypercholesterolemia and the risk of BCR in Afro-Caribbean men with PCa after RP (86). Allott et al. also found that high cholesterol was not associated with progression of PCa after RP or RT (40). Therefore, it was still controversial and more studies were needed.

We also observed that serum PSA level was significantly lower in statin users compared with non-users in many included studies (46, 57, 59, 62, 65). It was reported that PSA level could be influenced by smoking status, Gleason score, and 5α-reductase inhibitor for benign prostate hyperplasia treatment, but not associated with other clinical factors including hypercholesterolemia in a retrospective study (87, 88). An RCT study published by Murtola et al. in 2018 showed that 80 mg/day of atorvastatin could not significantly reduce the tumor proliferation index (Ki-67) and PSA level, but in subgroup analyses, atorvastatin use over 28 days exhibited a significant reduction in Ki-67 and PSA (89). Therefore, it was possible that statin use could only cover the truth of BCR and disease progression through decreasing the PSA level instead of preventing BCR. However, if this hypothesis was true, the detection of BCR would be delayed and the prognosis would be worse. However, the previously published meta-analysis found that statins have a significant effect on the reduction of
tumor metastasis, all-cause mortality, and PCSM after treatment (33), which indicated a better prognosis and was contradictory to this hypothesis.

In this review, we have also used various methods to detect, evaluate, and diminish the probable heterogeneity and publication bias of included studies. For studies about the HR of BCR, the sensitivity analysis and cumulative meta-analysis all showed a stable pooled result. The funnel plot, Begg’s test, and Egger’s test all exhibited little publication bias from qualitative and quantitative perspectives, respectively. After the trim-and-fill method, the pooled result also had a statistical significance. However, as for studies about the RR of BCR, there did exist a relatively high heterogeneity and publication bias. This could result from the limited number of included studies, and RR did show a stable pooled result. The funnel plot, Begg’s test, and Egger’s test all exhibited little publication bias from qualitative and quantitative perspectives, respectively. After the trim-and-fill method, the pooled result also had a statistical significance. However, as for studies about the RR of BCR, there did exist a relatively high heterogeneity and publication bias. This could result from the limited number of included studies, and RR did
not take time into consideration, which could lead into bias in the methodology. We also used the QE model, which took the quality of studies into account, to reevaluate the pooled results of RR and HR. Not surprisingly, the pHR remained stable with a statistical significance, which further proved that our results were religious and authentic.

Nevertheless, there still existed many limitations in our review. First, the definitions of statin use were various in the included studies. Information about the types of statins, the duration of statin use, the dose of statins, and the initiation of statin use (before or after primary treatment) was not complete and detailed in the included studies. Therefore, we could not take this into consideration, which will definitely contribute to the heterogeneity of studies. Second, there existed great heterogeneity in the characteristics of the studying cohort. Many patients in the statin group had preexisting comorbidities such as cardiovascular diseases and metabolic syndrome, which could influence the progression of PCa. Third, the characteristics of PCa could also be a potential confounder of the results. Although tumor stage did not show a statistical significance in the meta-regression, the GS, metastasis status, PCa volume, and surgical margin status could all be connected with BCR and contribute to the heterogeneity of studies. Fourth, although we have performed subgroup analyses according to the primary treatment, many patients did not accept only one kind of treatment and part of patients also accepted ADT after RT or RP, which could interfere with the result of subgroup analyses. Fifth, although many studies have provided the results adjusted for important covariates, some unadjusted results might influence the final pooled effect. Finally, although the pHR showed that statins lowered the BCR of PCa, the upper confidence interval was close to 1.00. Thus, the result needs to be deliberately explained.

In conclusion, despite some limitations, our study suggests that statin, a widely used and relatively cheap drug, has a unique role in the reduction of BCR in patients with PCa after definitive treatment, especially RT. In the future, more clinical trials and in vitro and animal experiments were needed to further verify the effects of statins in PCa and the mechanisms behind this phenomenon.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
AUTHOR CONTRIBUTIONS

J-XS, X-YZ, Z-BZ, Q-DX, and S-GW contributed to developing the main research question, carrying out the literature search, collecting the included studies’ information, and describing the results. J-XS performed the meta-analysis and wrote the first draft of the manuscript. C-QL and J-ZX contributed to the article and approved the submitted version. J-XS, Z-BZ, Q-DX, and S-GW contributed equally to this work.

FUNDING

This work was supported by the Natural Science Foundation of China (81772729) and Undergraduate Training Program for Innovation and Entrepreneurship (DELC2022010).

ACKNOWLEDGMENTS

We thank all the R programming package developers.

REFERENCES

1. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med (2018) 8(12):030361. doi: 10.1101/cshperspect.a030361
2. Liu X, Yu C, Bi Y, Zhang ZL. Trends and Age-Period-Cohort Effect on Incidence and Mortality of Prostate Cancer From 1990 to 2017 in China. Public Health (2019) 172:70–80. doi: 10.1016/j.puhe.2019.04.016
3. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-ENAM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment With Curative Intent. Eur Urol (2021) 79(2):243–62. doi: 10.1016/j.eurouro.2020.09.042
4. Amaro A, Esposito AI, Gallina A, Nee M, Angelini G, Albinini A, et al. Validation of Proposed Prostate Cancer Biomarkers With Gene Expression Data: A Long Road to Travel. Cancer Metastasis Rev (2014) 33(2):657–71. doi: 10.1007/s10555-013-9470-4
5. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer Progression and Survival Rates Following Anatomical Radical Retropubic Prostatectomy in 3,478 Consecutive Patients: Long-Term Results. J Urol (2004) 172(3):910–4. doi: 10.1097/01.ju.0000134888.22332.bb
6. Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of Different Definitions of Biochemical Failure After External Beam Radiotherapy Changes Conclusions About Relative Treatment Efficacy for Localized Prostate Cancer. Urology (2006) 68(3):593–8. doi: 10.1016/j.urology.2006.03.075
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural History of Progression After PSA Elevation Following Radical Prostatectomy. J Am Med Assoc (1999) 281(17):1591–7. doi: 10.1001/jama.281.17.1591
8. Boorjian SA, Thompson RH, Tolleson MK, Rangel Lj, Bergstralh EJ, Blute ML, et al. Long-Term Risk of Clinical Prostate Cancer After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time From Surgery to Recurrence. Eur Urol (2011) 59(6):893–9. doi: 10.1016/j.euro.2011.02.026
9. Lu J, Zhang L, Lu Y, Su M, Li X, Liu J, et al. Secondary Prevention of Cardiovascular Disease in China. Heart (2020) 106(17):1349–56. doi: 10.1136/heartjnl-2019-315884
10. Giovannone R, Busetto GM, Antonini G, De Cobelli O, Ferro M, Tricarico S, et al. Hyperhomocysteinemia as an Early Predictor of Erectile Dysfunction: International Index of Erectile Function (IIEF) and Penile Doppler Ultrasound Correlation With Plasma Levels of Homocysteine. Med (Baltimore) (2015) 94(39):e1556. doi: 10.1097/MD.0000000000001556
11. Kostis JB, Dobrzyński JM. Statins and Erectile Dysfunction. World J Mens Health (2019) 37(1):1–3. doi: 10.5534/wjmh.180015
12. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the Risk of Colorectal Cancer. N Engl J Med (2005) 352(21):2184–92. doi: 10.1056/NEJMoa043792
13. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin Drugs and Risk of Advanced Prostate Cancer. J Natl Cancer Inst (2006) 98(24):1819–25. doi: 10.1093/jnci/djg499
14. Shannon J, Tewodros E, Garzotto M, Beer TM, Derenick R, Palma A, et al. Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer. Front Endocrinol (2019) 372:4. doi: 10.3389/fned.2019.00155
15. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The Risk of Different De
a
citions of Biochemical Failure After External Beam Radiotherapy Changes Conclusions About Relative Treatment Efficacy for Localized Prostate Cancer. Urology (2006) 68(3):593–8. doi: 10.1016/j.urology.2006.03.075
16. Zhang P, Liu B. Statin Use and the Risk of Multiple Myeloma: A PRISMA-Compliant Meta-Analysis. Ann Hematol (2020) 99(8):1805–12. doi: 10.1007/s00277-020-04157-5
17. Wang Y, Li Q, Yuan Z, Ma S, Shao S, Wu Y, et al. Statin Use and Benefits of Thyroid Function: A Retrospective Cohort Study. Front Endocrinol (Lausanne) (2021) 12:578909. doi: 10.3389/fendo.2021.578909
18. Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The Current Evidence on Statin Use and Prostate Cancer Prevention: Are We There Yet? Nat Rev Urol (2017) 14(2):107–19. doi: 10.1038/nrurol.2016.199
19. Schaffner CP. Prostatic Cholesterol Metabolism: Regulation and Alteration. Prog Clin Biol Res (1981) 75:279–324.
20. Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, et al. Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer.
37. Huynh LM, Nayan M, Finelli A, Komissarenko M, Timilshina N, Kulkarni GS, et al. Statin Use and Time to Progression in Men on Active Surveillance for Prostate Cancer. *Prostate Cancer Prostatic Dis* (2020) 24(4):259–66. doi: 10.1038/s41391-019-0003-x

38. Allott EH, Farnan L, Steck SE, Song L, Arab L, Su LJ, et al. Statin Use, High Cholesterol and Prostate Cancer Progression; Results From HCaP-NC. *Prostate* (2018) 78(11):857–64. doi: 10.1002/pros.23644

39. Keski-Kuula T, Vuorio P, Visakorpi T, Tammela TJL, Murtoja TJ. Statin Use and Risk of Disease Recurrence and Death After Radical Prostatectomy. *Prostate* (2016) 76(5):469–78. doi: 10.1002/pros.23138

40. Song C, Park J, Park J, Shim M, Kim A, Jeong IJ, et al. Statin Use After Radical Prostatectomy Reduces Biochemical Recurrence in Men With Prostate Cancer. *Prostate* (2015) 75(2):211–7. doi: 10.1002/pros.22907

41. Oh DS, Koontz B, Freedland SJ, Gerber L, Patel P, Lewis S, et al. Statin Use is Associated With Decreased Prostate Cancer Recurrence in Men Treated With Brachytherapy. *World J Urol* (2015) 33(1):93–7. doi: 10.1007/s00345-014-1281-x

42. Cuaron J, Pei X, Cohen GN, Cox BW, Yamada Y, Zelefsky MJ, et al. Statin Use Not Associated With Improved Outcomes in Patients Treated With Brachytherapy for Prostate Cancer. *Brachytherapy* (2015) 14(2):179–84. doi: 10.1016/j.brachy.2014.05.019

43. Dunzig MR, Kotamarti S, Ghandour RA, Rothberg MB, Dubow BP, Benson MC, et al. Synergism Between Metformin and Statins in Modifying the Risk of Biochemical Recurrence Following Radical Prostatectomy in Men With Diabetes. *Prostate Cancer Prostatic Dis* (2015) 18(1):63–8. doi: 10.1038/pcan.2014.47

44. Harshman LC, Wang X, Nakabayashi M, Xie W, Valencia L, Werner L, et al. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. *JAMA Oncol* (2015) 1(4):495–504. doi: 10.1001/jamaoncol.2015.0829

45. Ishak-Howard MB, Okoth LA, Cooney KA. Statin Use and the Risk of Recurrence After Radical Prostatectomy in a Cohort of Men With Inherited and/or Early-Onset Forms of Prostate Cancer. *Urology* (2014) 83(6):1356–61. doi: 10.1016/j.jurology.2014.02.015

46. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, et al. Postoperative Statin Use and Risk of Biochemical Recurrence Following Radical Prostatectomy: Results From the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. *BJU Int* (2014) 114(5):661–6. doi: 10.1111/bju.12720

47. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PJ, et al. Impact of Statin Use on Biochemical Recurrence in Patients Treated With Radical Prostatectomy. *Prostate Cancer Prostatic Dis* (2013) 16(4):367–71. doi: 10.1038/pcan.2013.31

48. Kontraros M, Varkarakis I, Ntoumas K, Delivouliotis C. Pathological Characteristics, Biochemical Recurrence and Functional Outcome in Radical Prostatectomy Patients on Statin Therapy. *Urologia Internationalis* (2013) 90(3):263–9. doi: 10.1111/j.1464-4069.2013.01539.x

49. Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin Use in Relation to Prostate Cancer Outcomes in a Population-Based Patient Cohort Study. *Prostate* (2013) 73(1):1214–22. doi: 10.1002/pros.22671

50. Chao C, Williams SG, Xu L, Chen J, Wallner LP, Porter KR, et al. Statin Therapy is Not Associated With Prostate Cancer Recurrence Among Patients Who Underwent Radiation Therapy. *Cancer Lett* (2013) 335(1):214–8. doi: 10.1016/j.canlet.2013.02.017

51. Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG. Use of Statins and Prostate Cancer Progression Among Patients Treated With Prostatectomy. *BJU Int* (2013) 111(6):954–62. doi: 10.1111/j.1464-410X.2012.11639.x

52. Mass AZ, Agalliu I, Laze J, Lepor H. Preoperative Statin Therapy is Not Associated With Biochemical Recurrence After Radical Prostatectomy: Our Experience and Meta-Analysis. *J Urol* (2012) 188(3):786–91. doi: 10.1016/j.juro.2012.05.011

53. Miraz V, Do C, Ihez JM, Elman B, Latorre LF, Portaleo D, et al. Is Statin Use Associated With D’Amico Risk Groups and Biochemical Recurrence After Radical Prostatectomy? *Prog Urol* (2012) 22(5):273–8. doi: 10.1016/j.purol.2011.11.001
From the SEARCH Database. Cancer Epidemiol Biomarkers Prev (2014) 23 (11):2349–56. doi: 10.1158/1055-9965.EPI-14-0458
76. Tan P, Wei S, Yang L, Tang Z, Cao D, Liu L, et al. Effects of Statins on Prostate Cancer Recurrence and Mortality After Definitive Therapy: A Systematic Review and Meta-Analysis. Sci Rep (2016) 6:29106. doi: 10.1038/srep29106
77. Chan KK, Oza AM, Siu LL. The Statins as Anticancer Agents. Clin Cancer Res (2003) 9(1):10–9.
78. Hutchinson J, Marigold L. Clinical Potential of Statins in Prostate Cancer Radiation Therapy. Anticancer Res (2017) 37(10):5363–72. doi: 10.21873/anticancer.11962
79. He Z, Yuan J, Shen F, Zeng F, Qi P, Wang Z, et al. Atorvastatin Enhances Effects of Radiotherapy on Prostate Cancer Cells and Xenograft Tumor Mice Through Triggering Interaction Between Bcl-2 and MSH2. Med Sci Monit (2020) 26:e923560. doi: 10.12692/msm.2020.e923560
80. Shen YA, Shih HW, Lin YC, Hsu HY, Wu TF, Tsai CH, et al. Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair. Front Pharmacol (2018) 9:6600. doi: 10.3389/fphar.2018.00660
81. Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, et al. The Impact of Statin Use on the Efficacy of Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer. Prostate (2017) 77 (13):1303–11. doi: 10.1002/pro23390
82. Syvälä H, Pennanen P, Bläuer M, Tammela TL, Murtoja TJ. Additive Inhibitory Effects of Simvastatin and Enalaprilamide on Androgen-Sensitive LNCaP-CaP and VCaP Cells. Biochem Biophys Res Commun (2016) 481(1-2):46–50. doi: 10.1016/j.bbrc.2016.11.021
83. Pelton K, Freeman MR, Solomon KR. Cholesterol and Prostate Cancer. Curr Opin Pharmacol (2012) 12(6):751–9. doi: 10.1016/j.coph.2012.07.006
84. Dickerman B, Mucci L. Metabolic Factors and Prostate Cancer Risk. Clin Chem (2019) 65(1):42–4. doi: 10.1373/clinchem.2018.287243
85. Eckhardt C, Sibera I, Krebs M, Sibera S, Spahn M, Kneitz B, et al. High Expression of Sterol-O-Acyl Transferase 1 (SOAT1), an Enzyme Involved in Cholesterol Metabolism, is Associated With Earlier Biochemical Recurrence in High Risk Prostate Cancer. Prostate Cancer Prostatic Dis (2021). doi: 10.1038/s41391-021-00431-3
86. Lefebvre F, Blanchet-Deverly A, Michineau L, Blanchet P, Multignier L, Brueau L. Metabolic Syndrome and Prostate Cancer in Afro-Caribbean Men. Prostate (2022) 82(3):359–65. doi: 10.1002/pros.24281
87. Tarantino G, Crocetto F, Vito CD, Martino R, Pandolfo SD, Creta M, et al. Clinical Factors Affecting Prostate-Specific Antigen Levels in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Retrospective Study. Future Sci OA (2021) 7(3):Fx0643. doi: 10.2144/fsoa-2020-0154
88. Busetto GM, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S, et al. Short-Term Pretreatment With a Dual 5α-Reductase Inhibitor Before Bipolar Transurethral Resection of the Prostate (B-TURP): Evaluation of Prostate Vascularity and Decreased Surgical Blood Loss in Large Prostates. BJU Int (2015) 116(1):117–23. doi: 10.1111/bju.12917
89. Murtoja TJ, Syvälä H, Tolonen T, Helminen M, Riiokonen J, Koskimäki J, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Eur Urol (2018) 74(6):697–701. doi: 10.1016/j.eururo.2018.06.037

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or that may be claimed to be manufactured, is not guaranteed or endorsed by the publisher.